Skip to main content
. Author manuscript; available in PMC: 2020 Jul 26.
Published in final edited form as: J Vis Exp. 2019 Jul 26;(149):10.3791/59915. doi: 10.3791/59915

Figure 3: Successes and pitfalls of monoplex and multiplex.

Figure 3:

(A) Monoplex assay of primary colon cancer with FOXP3 at position 3, fluorescent intensity label shown. (B) Multiplex assay of primary colon cancer with FOXP3 at position 3 and CD3 at position 2. (C) Monoplex assay of primary colon cancer with FOXP3 at position 1, fluorescent intensity label shown. (D) Multiplex assay of primary colon cancer with FOXP3 at position 1 and CD3 at position 2. (E) Multiplex assay of primary colon cancer with order of antibodies as follows: CD8 (yellow), CD3 (green), CD163 (orange), pancytokeratin (white), PD-L1 (magenta), FOXP3 (red), working DAPI (blue). (F) Multiplex assay of primary colon cancer with order of antibodies as follows: CD8 (yellow), CD3 (green), CD163 (orange), pancytokeratin (white), PD-L1 (magenta), FOXP3 (red), non-working DAPI (blue).